arrow
D

Diana Ferraro

ospedale civile di baggiovara azienda ospedaliero-universitaria di modena
H指数:38
被引数:4,666

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic value of the kappa free light chain index in multiple sclerosis under the 2024 CSF positivity criterion: a multicentre study in oligoclonal band-negative patients

2024年脑脊液阳性标准下κ游离轻链指数在多发性硬化中的诊断价值:一项在寡克隆带阴性患者中的多中心研究

2026-11-080
OA
Long‐Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow‐Up of the CladStop Cohort

多发性硬化患者完成克拉屈滨治疗后长期疾病控制:<scp>CladStop</scp>队列的扩展随访

2026-10-300
OAAI
Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry

生成式人工智能技术在多发性硬化症研究中合成数据生成中的验证:与意大利多发性硬化症登记处真实世界证据的比较

2026-10-140
PRE
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)

评估接受不同治疗方案序列治疗的视神经脊髓炎患者队列中长期严重不良事件风险的概况:意大利视神经脊髓炎及相关疾病登记研究(I-MS&amp;RD)(ProSA研究)结果

2026-07-040
PRE
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis

儿科起病多发性硬化中度疗效治疗后早期强化治疗的预测工具

2026-06-010
PRE
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study

低丙种球蛋白血症和严重感染在应用抗CD20制剂的多发性硬化患者中的研究:一项多中心研究

2025-01-012
OAAI
SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells

Anti-CD20-Treated进行性多发性硬化症患者的SARS-CoV-2疫苗接种反应显示抗原特异性B和T细胞免疫衰老

2024-08-170
OAAI
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

多发性硬化症患者SARS-CoV-2-specific细胞的免疫代谢分析揭示的免疫衰老和疫苗功效

2024-03-293
OAAI
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

多种疾病改善疗法在复发缓解型多发性硬化症中的有效性: 模拟多臂随机试验的因果推断

2023-07-062
PRE
Disability accrual in primary and secondary progressive multiple sclerosis

原发性和继发性进行性多发性硬化症的残疾累积

2023-04-174
OA
Comparative effectiveness in multiple sclerosis: A methodological comparison

多发性硬化症的比较效果: 方法学比较

2023-02-193
PRE
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study
2022-12-0221
PRE
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

整个怀孕期间暴露于那他珠单抗: 在意大利多发性硬化症女性队列中的有效性和安全性

2022-09-3015
PRE
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
2022-09-0119
OAAI
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
2022-06-2335
OA
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study
2022-06-1418
OA